Skip to content

Transplantation of faeces in ulcerative colitis; restoring nature*s homeostasis

Transplantation of faeces in ulcerative colitis; restoring nature*s homeostasis - TURN trial

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON36482
Enrollment
40
Registered
2011-11-08
Start date
2011-06-24
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease ulcerative colitis

Interventions

Patients will be treated with faecal transplantation, processed for duodenal-tube infusion. Faeces will be collected from a donor as well as the patient him/herself, in which their own faeces will b

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: *Age *18 *Ability to give informed consent *Established left sided ulcerative colitis according to the Lennard-Jones criteria *SCCAI (Simple Clinical Colitis Activity Index) of 4 - 11 *Endoscopic Mayo score of >1 *Stable dose of thiopurines, 5-ASA, or corticosteroids in preceding 8 weeks *Women need to use reliable contraceptives during participation in the study

Exclusion criteria

Exclusion criteria: * condition leading to profound immunosuppression o For example: HIV, infectious diseases leading to imunosuppression, bone marrow malignancies o Use of systemic chemotherapy * Anti-TNF treatment in preceding 2 months * Ciclosporine treatment in preceding 4 weeks * Prednisolone dose * 10 mg * Life expectancy * of the colon) o presence of a pouch due to surgery o Presence of stoma * Known intra-abdominal fistula * Pregnancy or women who give brestfeeding * Vasopressive medication, icu stay * Signs of ileus, diminished passage * Allergy to macrogol or substituents, eg peanuts, shellfish

Design outcomes

Primary

MeasureTime frame
* Complete clinical remission (SCCAI 1)

Secondary

MeasureTime frame
* Adverse events (AE) at t=3, t=6 and t=12 weeks * SCCAI score reduction at t=6 weeks (pairwise SSCAI reduction of > 1.5 points will be regarded as a relevant reduction (10)) * Frequency of bowel movements (starting to report at t= -2 weeks) * Reduction of Mayo endoscopic score at t=6 wk * Time to recurrence (recurrence is defined as a SCCAI of *4 and Mayo score *1 (10)) * Intra individual changes in presence of microbial DNA in faecal samples at t=0, t=6, and t=12 weeks after faecal transplantation. * Intra individual changes in presence of microbial DNA in mucosal biopsies at t=0, t=6, and t=12 weeks after faecal transplantation.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)